Skip to content

Released Nov 8, 2021, after the close

10-Q filed Nov 9, 2021, 40 days after period end · 0001162194-21-000087

Q3 2021 · 10-Q
Revenue$28.50M−28.5% vs Q3 2020−8.1% vs Q2 2021
Net Income-$13.84MN/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.18N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$19,612,000N/M
Operating Cash Flowderived-$9,494,000N/M
Free Cash Flowderived-$11,200,000N/M
Margins · derived
Operating margin-68.8%−55.1 pt vs Q3 2020
Net margin-48.6%−33.5 pt vs Q3 2020

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020Q3 2019Q3 2018
Revenue$28.50M$39.86M$26.50M$28.96M
Net Income-$13.84M-$6.00M-$12.89M-$14.75M
EPS Diluted-$0.18-$0.08-$0.19-$0.38

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR